Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications
Identifieur interne : 000E47 ( PascalFrancis/Corpus ); précédent : 000E46; suivant : 000E48Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications
Auteurs : Joanne Ryan ; Marie-Laure AncelinSource :
- Drugs : (Basel) [ 0012-6667 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuating estrogen levels and low levels have been associated with depressed mood and there is strong support for a beneficial effect of estrogen-containing hormone treatment in depressed peri-menopausal women. Estrogen exerts its biological effects in large part through intracellular activation of its principal receptors, estrogen receptor α (ESR1) and estrogen receptor β (ESR2). Genetic variation in the estrogen receptors may therefore modify estrogen signalling, thus influencing a woman's susceptibility to developing depression. This review provides a synthesis of studies that have examined the association between estrogen receptor polymorphisms and depression-related mood disorders across the lifetime. Studies were identified through a search of the literature from January 1980 until March 2012 using MEDLINE, Web of Knowledge, Cochrane Library and PsycINFO databases. The studies conducted to date have produced inconsistent findings, which likely relates to the large heterogeneity in terms of the populations, study design and depression measures used. It appears unlikely that the common ESR1 variants rs2234693 and rs9340799 are associated with moderate depressive symptoms in women; however, there is some evidence that indicates a significant association with more severe depressive symptoms, major depressive disorder and anxiety. There are too few studies of ESR2 polymorphisms to draw any definite conclusions; however, preliminary evidence suggests that specific variants may modify the risk of depression associated with the use of hormone treatment in women. Few studies have investigated associations in men, and they have focused almost exclusively on ESR1, but all report non-significant findings. Much work is therefore still needed in this field. If it is confirmed that specific estrogen receptor polymorphisms are associated with the risk of depression, this could have important preventive and therapeutic implications, with the potential to develop targeted estrogen receptor agonists and antagonists. Furthermore, it is possible that such therapies may be more effective in treating particular people with depression based on their genetic profile, which is an exciting prospect given that many people do not respond to current antidepressant treatments.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 12-0459513 INIST |
---|---|
ET : | Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications |
AU : | RYAN (Joanne); ANCELIN (Marie-Laure) |
AF : | Inserm U1061/Montpellier/France (1 aut., 2 aut.); University Montpellier 1, U1061/Montpellier/France (1 aut., 2 aut.); Murdoch Children's Research Institute (MCRI), Royal Children's Hospital/Parkville, VIC/Australie (1 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Drugs : (Basel); ISSN 0012-6667; Coden DRUGAY; Nouvelle-Zélande; Da. 2012; Vol. 72; No. 13; Pp. 1725-1738; Bibl. 117 ref. |
LA : | Anglais |
EA : | Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuating estrogen levels and low levels have been associated with depressed mood and there is strong support for a beneficial effect of estrogen-containing hormone treatment in depressed peri-menopausal women. Estrogen exerts its biological effects in large part through intracellular activation of its principal receptors, estrogen receptor α (ESR1) and estrogen receptor β (ESR2). Genetic variation in the estrogen receptors may therefore modify estrogen signalling, thus influencing a woman's susceptibility to developing depression. This review provides a synthesis of studies that have examined the association between estrogen receptor polymorphisms and depression-related mood disorders across the lifetime. Studies were identified through a search of the literature from January 1980 until March 2012 using MEDLINE, Web of Knowledge, Cochrane Library and PsycINFO databases. The studies conducted to date have produced inconsistent findings, which likely relates to the large heterogeneity in terms of the populations, study design and depression measures used. It appears unlikely that the common ESR1 variants rs2234693 and rs9340799 are associated with moderate depressive symptoms in women; however, there is some evidence that indicates a significant association with more severe depressive symptoms, major depressive disorder and anxiety. There are too few studies of ESR2 polymorphisms to draw any definite conclusions; however, preliminary evidence suggests that specific variants may modify the risk of depression associated with the use of hormone treatment in women. Few studies have investigated associations in men, and they have focused almost exclusively on ESR1, but all report non-significant findings. Much work is therefore still needed in this field. If it is confirmed that specific estrogen receptor polymorphisms are associated with the risk of depression, this could have important preventive and therapeutic implications, with the potential to develop targeted estrogen receptor agonists and antagonists. Furthermore, it is possible that such therapies may be more effective in treating particular people with depression based on their genetic profile, which is an exciting prospect given that many people do not respond to current antidepressant treatments. |
CC : | 002B18C07A |
FD : | Polymorphisme; Variabilité génétique; Génotype; Récepteur hormonal; Récepteur oestrogène; Facteur risque; Etat dépressif; Traitement; Article synthèse; Pathogénie; Comparaison interindividuelle; Revue bibliographique |
FG : | Trouble de l'humeur |
ED : | Polymorphism; Genetic variability; Genotype; Hormonal receptor; Estrogen receptor; Risk factor; Depression; Treatment; Review; Pathogenesis; Interindividual comparison; Bibliographic review |
EG : | Mood disorder |
SD : | Polimorfismo; Variabilidad genética; Genotipo; Receptor hormonal; Receptor estrógeno; Factor riesgo; Estado depresivo; Tratamiento; Artículo síntesis; Patogenia; Comparación interindividual; Revista bibliográfica |
LO : | INIST-15326.354000508385810030 |
ID : | 12-0459513 |
Links to Exploration step
Pascal:12-0459513Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications</title>
<author><name sortKey="Ryan, Joanne" sort="Ryan, Joanne" uniqKey="Ryan J" first="Joanne" last="Ryan">Joanne Ryan</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University Montpellier 1, U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Murdoch Children's Research Institute (MCRI), Royal Children's Hospital</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ancelin, Marie Laure" sort="Ancelin, Marie Laure" uniqKey="Ancelin M" first="Marie-Laure" last="Ancelin">Marie-Laure Ancelin</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University Montpellier 1, U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0459513</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0459513 INIST</idno>
<idno type="RBID">Pascal:12-0459513</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications</title>
<author><name sortKey="Ryan, Joanne" sort="Ryan, Joanne" uniqKey="Ryan J" first="Joanne" last="Ryan">Joanne Ryan</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University Montpellier 1, U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Murdoch Children's Research Institute (MCRI), Royal Children's Hospital</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ancelin, Marie Laure" sort="Ancelin, Marie Laure" uniqKey="Ancelin M" first="Marie-Laure" last="Ancelin">Marie-Laure Ancelin</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University Montpellier 1, U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bibliographic review</term>
<term>Depression</term>
<term>Estrogen receptor</term>
<term>Genetic variability</term>
<term>Genotype</term>
<term>Hormonal receptor</term>
<term>Interindividual comparison</term>
<term>Pathogenesis</term>
<term>Polymorphism</term>
<term>Review</term>
<term>Risk factor</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Polymorphisme</term>
<term>Variabilité génétique</term>
<term>Génotype</term>
<term>Récepteur hormonal</term>
<term>Récepteur oestrogène</term>
<term>Facteur risque</term>
<term>Etat dépressif</term>
<term>Traitement</term>
<term>Article synthèse</term>
<term>Pathogénie</term>
<term>Comparaison interindividuelle</term>
<term>Revue bibliographique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuating estrogen levels and low levels have been associated with depressed mood and there is strong support for a beneficial effect of estrogen-containing hormone treatment in depressed peri-menopausal women. Estrogen exerts its biological effects in large part through intracellular activation of its principal receptors, estrogen receptor α (ESR1) and estrogen receptor β (ESR2). Genetic variation in the estrogen receptors may therefore modify estrogen signalling, thus influencing a woman's susceptibility to developing depression. This review provides a synthesis of studies that have examined the association between estrogen receptor polymorphisms and depression-related mood disorders across the lifetime. Studies were identified through a search of the literature from January 1980 until March 2012 using MEDLINE, Web of Knowledge, Cochrane Library and PsycINFO databases. The studies conducted to date have produced inconsistent findings, which likely relates to the large heterogeneity in terms of the populations, study design and depression measures used. It appears unlikely that the common ESR1 variants rs2234693 and rs9340799 are associated with moderate depressive symptoms in women; however, there is some evidence that indicates a significant association with more severe depressive symptoms, major depressive disorder and anxiety. There are too few studies of ESR2 polymorphisms to draw any definite conclusions; however, preliminary evidence suggests that specific variants may modify the risk of depression associated with the use of hormone treatment in women. Few studies have investigated associations in men, and they have focused almost exclusively on ESR1, but all report non-significant findings. Much work is therefore still needed in this field. If it is confirmed that specific estrogen receptor polymorphisms are associated with the risk of depression, this could have important preventive and therapeutic implications, with the potential to develop targeted estrogen receptor agonists and antagonists. Furthermore, it is possible that such therapies may be more effective in treating particular people with depression based on their genetic profile, which is an exciting prospect given that many people do not respond to current antidepressant treatments.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0012-6667</s0>
</fA01>
<fA02 i1="01"><s0>DRUGAY</s0>
</fA02>
<fA03 i2="1"><s0>Drugs : (Basel)</s0>
</fA03>
<fA05><s2>72</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RYAN (Joanne)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ANCELIN (Marie-Laure)</s1>
</fA11>
<fA14 i1="01"><s1>Inserm U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University Montpellier 1, U1061</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Murdoch Children's Research Institute (MCRI), Royal Children's Hospital</s1>
<s2>Parkville, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>1725-1738</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15326</s2>
<s5>354000508385810030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>117 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0459513</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Drugs : (Basel)</s0>
</fA64>
<fA66 i1="01"><s0>NZL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuating estrogen levels and low levels have been associated with depressed mood and there is strong support for a beneficial effect of estrogen-containing hormone treatment in depressed peri-menopausal women. Estrogen exerts its biological effects in large part through intracellular activation of its principal receptors, estrogen receptor α (ESR1) and estrogen receptor β (ESR2). Genetic variation in the estrogen receptors may therefore modify estrogen signalling, thus influencing a woman's susceptibility to developing depression. This review provides a synthesis of studies that have examined the association between estrogen receptor polymorphisms and depression-related mood disorders across the lifetime. Studies were identified through a search of the literature from January 1980 until March 2012 using MEDLINE, Web of Knowledge, Cochrane Library and PsycINFO databases. The studies conducted to date have produced inconsistent findings, which likely relates to the large heterogeneity in terms of the populations, study design and depression measures used. It appears unlikely that the common ESR1 variants rs2234693 and rs9340799 are associated with moderate depressive symptoms in women; however, there is some evidence that indicates a significant association with more severe depressive symptoms, major depressive disorder and anxiety. There are too few studies of ESR2 polymorphisms to draw any definite conclusions; however, preliminary evidence suggests that specific variants may modify the risk of depression associated with the use of hormone treatment in women. Few studies have investigated associations in men, and they have focused almost exclusively on ESR1, but all report non-significant findings. Much work is therefore still needed in this field. If it is confirmed that specific estrogen receptor polymorphisms are associated with the risk of depression, this could have important preventive and therapeutic implications, with the potential to develop targeted estrogen receptor agonists and antagonists. Furthermore, it is possible that such therapies may be more effective in treating particular people with depression based on their genetic profile, which is an exciting prospect given that many people do not respond to current antidepressant treatments.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B18C07A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Polymorphisme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Polymorphism</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Polimorfismo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Variabilité génétique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Genetic variability</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Variabilidad genética</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Génotype</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Genotype</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Genotipo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur hormonal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Hormonal receptor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor hormonal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur oestrogène</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Estrogen receptor</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor estrógeno</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Depression</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Review</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pathogénie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pathogenesis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Patogenia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Comparaison interindividuelle</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Interindividual comparison</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Comparación interindividual</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Revue bibliographique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Bibliographic review</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Revista bibliográfica</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>37</s5>
</fC07>
<fN21><s1>353</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 12-0459513 INIST</NO>
<ET>Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications</ET>
<AU>RYAN (Joanne); ANCELIN (Marie-Laure)</AU>
<AF>Inserm U1061/Montpellier/France (1 aut., 2 aut.); University Montpellier 1, U1061/Montpellier/France (1 aut., 2 aut.); Murdoch Children's Research Institute (MCRI), Royal Children's Hospital/Parkville, VIC/Australie (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Drugs : (Basel); ISSN 0012-6667; Coden DRUGAY; Nouvelle-Zélande; Da. 2012; Vol. 72; No. 13; Pp. 1725-1738; Bibl. 117 ref.</SO>
<LA>Anglais</LA>
<EA>Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuating estrogen levels and low levels have been associated with depressed mood and there is strong support for a beneficial effect of estrogen-containing hormone treatment in depressed peri-menopausal women. Estrogen exerts its biological effects in large part through intracellular activation of its principal receptors, estrogen receptor α (ESR1) and estrogen receptor β (ESR2). Genetic variation in the estrogen receptors may therefore modify estrogen signalling, thus influencing a woman's susceptibility to developing depression. This review provides a synthesis of studies that have examined the association between estrogen receptor polymorphisms and depression-related mood disorders across the lifetime. Studies were identified through a search of the literature from January 1980 until March 2012 using MEDLINE, Web of Knowledge, Cochrane Library and PsycINFO databases. The studies conducted to date have produced inconsistent findings, which likely relates to the large heterogeneity in terms of the populations, study design and depression measures used. It appears unlikely that the common ESR1 variants rs2234693 and rs9340799 are associated with moderate depressive symptoms in women; however, there is some evidence that indicates a significant association with more severe depressive symptoms, major depressive disorder and anxiety. There are too few studies of ESR2 polymorphisms to draw any definite conclusions; however, preliminary evidence suggests that specific variants may modify the risk of depression associated with the use of hormone treatment in women. Few studies have investigated associations in men, and they have focused almost exclusively on ESR1, but all report non-significant findings. Much work is therefore still needed in this field. If it is confirmed that specific estrogen receptor polymorphisms are associated with the risk of depression, this could have important preventive and therapeutic implications, with the potential to develop targeted estrogen receptor agonists and antagonists. Furthermore, it is possible that such therapies may be more effective in treating particular people with depression based on their genetic profile, which is an exciting prospect given that many people do not respond to current antidepressant treatments.</EA>
<CC>002B18C07A</CC>
<FD>Polymorphisme; Variabilité génétique; Génotype; Récepteur hormonal; Récepteur oestrogène; Facteur risque; Etat dépressif; Traitement; Article synthèse; Pathogénie; Comparaison interindividuelle; Revue bibliographique</FD>
<FG>Trouble de l'humeur</FG>
<ED>Polymorphism; Genetic variability; Genotype; Hormonal receptor; Estrogen receptor; Risk factor; Depression; Treatment; Review; Pathogenesis; Interindividual comparison; Bibliographic review</ED>
<EG>Mood disorder</EG>
<SD>Polimorfismo; Variabilidad genética; Genotipo; Receptor hormonal; Receptor estrógeno; Factor riesgo; Estado depresivo; Tratamiento; Artículo síntesis; Patogenia; Comparación interindividual; Revista bibliográfica</SD>
<LO>INIST-15326.354000508385810030</LO>
<ID>12-0459513</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:12-0459513 |texte= Polymorphisms of Estrogen Receptors and Risk of Depression: Therapeutic Implications }}
This area was generated with Dilib version V0.6.33. |